2023 World Conference on Lung Cancer (Posters)-P2.14. Outcomes of Chemoimmunotherapy in Patients with ES-SCLC According to Liver Metastasis: A Multicenter Prospective Cohort Study

P2.14. Outcomes of Chemoimmunotherapy in Patients with ES-SCLC According to Liver Metastasis: A Multicenter Prospective Cohort Study - PDF(Slides)

Back to course

Pdf Summary

This study examined the outcomes of chemoimmunotherapy in patients with ES-small cell lung cancer (SCLC) according to the presence of liver metastasis. The researchers conducted a multicenter prospective cohort study involving patients who received carboplatin and etoposide with atezolizumab. Tumor samples obtained before treatment were analyzed using RNA-seq and IHC staining.<br /><br />The study included a total of 208 patients, with 137 tumor tissue samples collected. The analysis population consisted of 72 patients. The results showed that patients with liver metastasis had a significantly shorter progression-free survival (PFS) and overall survival (OS) compared to those without liver metastasis. In the overall population, the hazard ratio (HR) for disease progression or death in patients with liver metastasis was 1.81 for PFS and 2.21 for OS. In the RNA analysis population, the HRs were 1.58 for PFS and 1.62 for OS.<br /><br />Further analysis revealed that patients without liver metastasis had higher CD8 T cell signature scores and elevated CD8 T cell expression compared to those with liver metastasis. This suggests that patients with liver metastasis had less infiltration of CD8 T cells in the tumor, potentially contributing to poor chemoimmunotherapy outcomes.<br /><br />In conclusion, liver metastasis was identified as an independent negative predictive factor for the outcome of chemoimmunotherapy in patients with ES-SCLC. The study provided insights into the immunological differences associated with liver metastasis. It should be noted that the study was funded by Chugai Pharmaceutical Co Ltd.

Asset Subtitle

Yuhei Harutani

Meta Tag

Speaker Yuhei Harutani

Topic SCLC & Neuroendocrine Tumors: First Line Therapy

Keywords

chemoimmunotherapy

ES-small cell lung cancer

SCLC

liver metastasis

carboplatin

etoposide

atezolizumab

RNA-seq

IHC staining

CD8 T cells